Document Detail

Working capacity is increased following recombinant human erythropoietin treatment.
MedLine Citation:
PMID:  3199672     Owner:  NLM     Status:  MEDLINE    
To investigate the effect of partial correction of anemia in patients maintained by chronic intermittent hemodialysis on aerobic and anaerobic working capacity, eight patients underwent a bicycle spiro-ergometry before and after treatment with recombinant human erythropoietin (r-HuEPO). the initial mean (+/- SD) hemoglobin value was 5.9 mg/dl +/- 0.61 and increased during treatment to 10.9 +/- 0.59 mg/dl, P less than 0.0001). This partial correction of anemia resulted in a significant increase of both oxygen uptake at the anaerobic threshold and peak peripheral oxygen uptake at subjective exhaustion (P less than 0.01 and P less than 0.0002, respectively). The increase in oxygen uptake corresponded to significant increases in Watts, both at the anaerobic threshold and at maximum workload (P less than 0.02 and P less than 0.0004). These data show that partial correction of renal anemia results in a significant increase of both exercise capacity and maximum work.
G Mayer; J Thum; E M Cada; H K Stummvoll; H Graf
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Kidney international     Volume:  34     ISSN:  0085-2538     ISO Abbreviation:  Kidney Int.     Publication Date:  1988 Oct 
Date Detail:
Created Date:  1989-01-25     Completed Date:  1989-01-25     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0323470     Medline TA:  Kidney Int     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  525-8     Citation Subset:  IM    
2nd Department of Medicine, University of Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia / physiopathology,  therapy*
Erythropoietin / therapeutic use*
Middle Aged
Oxygen Consumption / drug effects
Physical Exertion*
Recombinant Proteins / therapeutic use
Renal Dialysis
Reg. No./Substance:
0/Recombinant Proteins; 11096-26-7/Erythropoietin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A six-year comparison of patient and technique survivals in CAPD and HD.
Next Document:  Metabolism of complement factor D in renal failure.